Teriparatide
Also known as: Forteo, PTH 1-34, recombinant human parathyroid hormone
Teriparatide is a synthetic fragment of human parathyroid hormone (PTH 1-34) that stimulates bone formation by activating osteoblast activity. This FDA-approved peptide represents the first anabolic agent for osteoporosis treatment, directly promoting new bone tissue growth rather than simply preventing bone loss.
Teriparatide is a 4117.8 Da research peptide. Teriparatide is a synthetic fragment of human parathyroid hormone (PTH 1-34) that stimulates bone formation by activating osteoblast activity. This FDA-approved peptide represents the first anabolic agent for osteoporosis treatment, directly promoting new bone tissue growth rather than simply preventing bone loss.
Also called: Forteo, PTH 1-34, recombinant human parathyroid hormone
4117.8
Molecular Weight
Daltons
3
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
20-20
Typical Dose
mcg
Overview
Teriparatide functions as a potent bone anabolic agent by mimicking the action of the first 34 amino acids of endogenous parathyroid hormone. When administered intermittently, this peptide activates PTH/PTHrP receptors on osteoblasts, triggering a cascade of bone-building processes. The peptide upregulates cyclic adenosine monophosphate (cAMP) signaling, which stimulates osteoblast proliferation, differentiation, and matrix synthesis. Unlike continuous PTH exposure that promotes bone resorption, pulsatile teriparatide administration creates a net anabolic effect by increasing osteoblast activity more than osteoclast activity. Research demonstrates that teriparatide enhances trabecular connectivity, increases cortical thickness, and improves overall bone microarchitecture. The peptide also stimulates insulin-like growth factor-1 (IGF-1) production and enhances calcium absorption in the intestines. Clinical studies show significant increases in bone mineral density at both spine and hip locations, with corresponding reductions in vertebral and non-vertebral fracture risk.
Key Takeaways: Teriparatide
- Strongest evidence supports Teriparatide for increased bone mineral density and reduced vertebral fracture risk
- Research doses typically range from 20 to 20 mcg via subcutaneous
- 3 benefits with strong evidence, 3 moderate, 1 preliminary
- Half-life: 1 hour (subcutaneous)
- 4 cited research studies in this guide
Mechanism of Action
Teriparatide binds to PTH/PTHrP receptors on osteoblasts and activates adenylyl cyclase, increasing intracellular cAMP levels. This activation stimulates protein kinase A, which phosphorylates CREB transcription factors. Phosphorylated CREB promotes expression of genes involved in osteoblast differentiation and bone matrix synthesis, including alkaline phosphatase, osteocalcin, and type I collagen. The peptide also inhibits osteoblast apoptosis through activation of survival signaling pathways. Intermittent administration prevents receptor desensitization and maintains the anabolic window for bone formation.
Research Benefits
Teriparatide at a Glance
Teriparatide binds to PTH/PTHrP receptors on osteoblasts and activates adenylyl cyclase, increasing intracellular cAMP levels.
Increased Bone Mineral Density
Strong EvidenceTeriparatide increases lumbar spine BMD by 6-14% and femoral neck BMD by 2-6% after 18-24 months of treatment. The peptide stimulates both trabecular and cortical bone formation through enhanced osteoblast activity.
Reduced Vertebral Fracture Risk
Strong EvidenceClinical trials demonstrate a 65-69% reduction in new vertebral fractures compared to placebo. This protection stems from improved trabecular connectivity and increased vertebral bone strength.
Enhanced Bone Microarchitecture
Strong EvidenceHigh-resolution imaging studies show teriparatide improves trabecular thickness, number, and connectivity while reducing trabecular separation. These microstructural improvements contribute to enhanced bone strength beyond BMD gains.
Accelerated Fracture Healing
Moderate EvidenceResearch indicates teriparatide can reduce fracture healing time by 30-40% by stimulating callus formation, enhancing angiogenesis at fracture sites, and promoting osteoblast recruitment to healing bone.
Improved Cortical Bone Properties
Moderate EvidenceStudies show teriparatide increases cortical thickness and reduces cortical porosity, particularly at the hip and radius. These changes enhance the mechanical properties of long bones.
Prevention of Bone Loss in Hypogonadal States
Moderate EvidenceResearch suggests teriparatide can prevent or reverse bone loss associated with hypogonadism, glucocorticoid use, and other secondary causes of osteoporosis through direct anabolic stimulation.
Enhanced Calcium Absorption
PreliminaryTeriparatide increases intestinal calcium absorption by upregulating vitamin D receptor expression and enhancing 1,25-dihydroxyvitamin D3 synthesis in the kidneys.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Osteoporosis treatment research | 20–20 mcg | subcutaneous |
| Fracture healing studies | 20–40 mcg | subcutaneous |
| Bone formation biomarker research | 10–40 mcg | subcutaneous |
Frequency
Once daily
Timing
Same time each day, rotate injection sites
Cycle Length
Maximum 24 months lifetime exposure in clinical studies
Research Notes
- 1Administer at consistent time daily to maintain anabolic effects
- 2Rotate injection sites (thigh, abdomen) to prevent lipodystrophy
- 3Allow to reach room temperature before injection
- 4Do not shake the pen device to prevent protein denaturation
- 5Monitor serum calcium levels during initial treatment period
Reconstitution Guide
Standard Reconstitution
Vial Size
600 mg
Bacteriostatic Water
2.4 mL
Concentration
2500 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Teriparatide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2.4 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 28 days after first use.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
28 days after first use
Important Notes
- •Available as pre-filled pen injectors containing 600 mcg/2.4mL
- •Do not freeze or expose to heat above 25°C
- •Protect from light during storage
- •Discard if solution becomes cloudy or contains particles
- •Single-use pen devices should not be shared between subjects
Teriparatide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Teriparatide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea (most common, affects 8-30% of users)
- !Injection site reactions (pain, swelling, bruising)
- !Dizziness and orthostatic hypotension
- !Leg cramps and muscle weakness
- !Hypercalcemia (elevated blood calcium)
- !Hypercalciuria (elevated urine calcium)
- !Headache and fatigue
- !Transient increase in serum uric acid
- !Potential osteosarcoma risk (theoretical, based on rat studies)
- !Kidney stones (rare but documented)
Potential Interactions
- ⚡Digoxin: Teriparatide-induced hypercalcemia may predispose to digoxin toxicity
- ⚡Thiazide diuretics: May exacerbate hypercalcemia when combined with teriparatide
- ⚡Calcium supplements: Concurrent use may increase risk of hypercalcemia
- ⚡Vitamin D supplements: High-dose vitamin D may potentiate hypercalcemic effects
- ⚡Loop diuretics: May increase calcium excretion and reduce teriparatide effectiveness
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Effect of recombinant human parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
Pivotal trial demonstrating 20 mcg daily teriparatide reduced vertebral fractures by 65% and increased spine BMD by 9% over 21 months in postmenopausal women with osteoporosis.
Effects of teriparatide on bone density and turnover in postmenopausal women with osteoporosis
Study showing teriparatide 20 mcg daily increased lumbar spine BMD by 13% and femoral neck BMD by 3% after 20 months, with rapid increases in bone formation markers.
Teriparatide accelerates fracture repair in a rat femoral osteotomy model
Preclinical study demonstrating teriparatide treatment enhanced callus formation, increased mechanical strength, and accelerated healing time in rat femoral fractures.
Effects of teriparatide on cortical bone in postmenopausal women with osteoporosis
Analysis showing teriparatide treatment for 18 months increased cortical thickness and cross-sectional area while improving estimated bone strength at multiple skeletal sites.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Bone formation markers increase within 1-3 months of starting teriparatide, while significant BMD gains typically appear after 6-12 months. Peak effects on bone density occur around 18-24 months of treatment.
The 24-month limit stems from rat studies showing increased osteosarcoma risk with prolonged high-dose exposure. While this risk hasn't been confirmed in humans, regulatory agencies maintain lifetime treatment limits as a precautionary measure.
Teriparatide should not be used concurrently with bisphosphonates as they may antagonize its bone-building effects. Sequential therapy (teriparatide followed by antiresorptive agents) is the recommended approach for optimal bone protection.
Without follow-up antiresorptive treatment, bone density gains from teriparatide begin to decline within 12 months. Sequential therapy with bisphosphonates or denosumab is typically recommended to maintain benefits.
Store teriparatide pens in the refrigerator (2-8°C) and protect from light. Allow to reach room temperature before injection, never shake the pen, and discard after 28 days of first use or if the solution appears cloudy.
Nausea is the most frequent side effect, occurring in 8-30% of users. Injection site reactions, dizziness, leg cramps, and transient increases in blood calcium are also common but usually mild and manageable.
Research suggests teriparatide may accelerate fracture healing by 30-40% through enhanced callus formation and increased bone formation at fracture sites. However, this use requires careful medical supervision and monitoring.
Clinical trials show teriparatide increases lumbar spine BMD by 6-14% and hip BMD by 2-6% over 18-24 months. These gains are typically larger and faster than those achieved with antiresorptive medications alone.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.